FDA Warning; WE ARE EXEMPT from Freedom of Info Act

FDA Approves Saphris Tablets (asenapine) To Treat Schizophrenia And Bipolar Disorder

when I went to look at the FDA at some of their memos to check on the tests, this is what I found:

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).



FDA Briefing Material


The company who did the research?  well, here is thier mission statement


WHO WE ARE

To earn trust, every day.

At Schering-Plough, we aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.

To achieve these goals and grow our company, we are working to earn the trust of all stakeholders. We understand that earning trust demands hard work, sharp execution, integrity and transparency.

Our customers and patients are our most important constituents. Our vision for the new Schering-Plough clearly sets forth what we will do as a global team, what makes us special as a company and what will give us a competitive advantage.